Skoglund L A, Ingebrigtsen K, Nafstad I, Jansen J H
J Appl Toxicol. 1987 Feb;7(1):1-6. doi: 10.1002/jat.2550070102.
The time development of the biodistribution and the hepatotoxicity following peroral administration of 14C-acetaminophen (APAP 400 or 800 mg.kg-1; 1 microCi) was characterized in a trial procedure using male Bom:NMRI mice. APAP (400 mg.kg-1) caused a transitory hepatic glutathione (GSH) depletion while APAP 800 mg.kg-1 maximally depleted hepatic GSH throughout the 12 h trial period. A lag time between the initial GSH depletion and the ensuing hepatic necrosis was seen. From 8 h post dosing a decrease of 14C-APAP or its metabolites coincided with recovery of the hepatic GHS level and the regeneration of the hepatic cells caused by APAP 400 mg.kg-1. Hepatic glycogen depletion preceded centrilobular necrosis, and irrespective of APAP dose definite kidney damage was absent. Irrespective of APAP dose the biodistribution of 14C-APAP or its metabolites was predominantly in organs associated with metabolism and excretion. After APAP (800 mg.kg-1) significant amounts of 14C-APAP or its metabolites were present up to 24 h post dosing. The operative status of the hepatic GSH conjugative system has an important influence on the rate of elimination of toxic APAP doses. Hepatic cell necrosis with a possible effect on the circulation may play an important secondary role in the elimination of toxic APAP doses. Factors which may influence the status of the hepatic GSH conjugative system and toxicokinetics of perorally administered APAP doses are discussed.
在一项使用雄性Bom:NMRI小鼠的试验程序中,对口服14C-对乙酰氨基酚(APAP 400或800 mg·kg-1;1微居里)后生物分布和肝毒性的时间发展进行了表征。APAP(400 mg·kg-1)导致短暂的肝脏谷胱甘肽(GSH)耗竭,而APAP 800 mg·kg-1在整个12小时试验期内最大程度地耗尽了肝脏GSH。观察到初始GSH耗竭与随后的肝坏死之间存在滞后时间。给药后8小时起,14C-APAP或其代谢产物的减少与肝脏GHS水平的恢复以及由APAP 400 mg·kg-1引起的肝细胞再生同时发生。肝糖原耗竭先于小叶中心坏死,且无论APAP剂量如何均无明显的肾损伤。无论APAP剂量如何,14C-APAP或其代谢产物的生物分布主要在与代谢和排泄相关的器官中。给予APAP(800 mg·kg-1)后,给药后24小时内仍存在大量的14C-APAP或其代谢产物。肝脏GSH结合系统的运行状态对毒性APAP剂量的消除速率有重要影响。可能影响循环的肝细胞坏死在毒性APAP剂量的消除中可能起重要的次要作用。讨论了可能影响肝脏GSH结合系统状态和口服APAP剂量毒代动力学的因素。